Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

(EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM

K-Number: K901840 · 1990-09-12

ApplicantGranbio, Inc.
Decision Date1990-09-12
Product CodeLJN
Advisory CommitteeMI
DecisionSubstantially Equivalent

Device Summary

(EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM is the device name listed in this FDA 510(k) record. The listed applicant is Granbio, Inc.. It received FDA 510(k) clearance on 1990-09-12 under 510(k) number K901840. The device is classified under product code LJN. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the (EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM?

(EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM is a medical device that received FDA 510(k) clearance on 1990-09-12. The listed applicant is Granbio, Inc.. The 510(k) number is K901840.

When did (EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM receive FDA 510(k) clearance?

(EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM received FDA 510(k) clearance on 1990-09-12, under 510(k) number K901840.

Who is the listed applicant for (EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM?

The FDA 510(k) record lists Granbio, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for (EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM?

The FDA product code for (EIA) FOR IGM ANTIBODY TO EBV VCA IN HUMAN SERUM is LJN.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Other records listing Granbio, Inc. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K951822EBNA ENZYME IMMUNOASSAY KITK934774UNKNOWNK901156EIA FOR IGG ANTIBODY TO EBV VCA IN HUMAN SERUMK881617INDIRECT IMMUNOFLUORESCENT ANTIBODY ASSAYK871298EBNA ACIF ASSAY KITK864347INDIRECT IMMUNOFLUORESCENT ANTIBODY ASSAY/ EBV-VCA

View all 8 devices →

Related Devices (Code: LJN)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K123021BIOPLEX 2200 EBV IGM KITBio-Rad LaboratoriesK073381PLEXUS EBV IGM MULTI-ANALYTE DIAGNOSTICS, MODEL: MP0600MFocus Diagnostics, Inc.K042092ATHENA MULTI-LYTE EBV VCA IGM TEST SYSTEMZeus Scientific, Inc.K033780MODIFICATION TO SERAQUEST VCA IGMQuest Intl., Inc.K990977SERAQUEST EB VAC IGMQuest Intl., Inc.K991459COPALIS EBV-M ANTIBODY ASSAYDiaSorin, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑